Can experimental models of rodent implantation glioma be improved? A study of pure and mixed glioma cell line tumours

被引:0
|
作者
Ian R. Whittle
Donald C. Macarthur
George P. Malcolm
Mingwei Li
Kate Washington
James W. Ironside
机构
[1] Department of Clinical Neurosciences,
[2] Western General Hospital,undefined
来源
Journal of Neuro-Oncology | 1998年 / 36卷
关键词
rodent glioma; neuropathology; immunocytochemistry; invasion;
D O I
暂无
中图分类号
学科分类号
摘要
To evaluate the hypothesis that co-implantation of different rodent glioma cell lines might result in experimental brain tumours that more closely resemble human gliomas the neuropathology and immunocytochemical features of implantation gliomas derived from single cell lines (C6, A15A5, F98), two cell lines admixed 50:50 prior to implantation (C6 + F98 and C6 + A15A5) and three cell lines equally admixed (C6 + A15A5 + F98) was studied in the adult Wistar rat. Tumours grew consistently following implantation of the single and the two admixed cell lines, however tumour growth following triple mix implantation was considerably and consistently impaired. The tumours derived from admixed cell lines showed regional heterogeneity with areas characteristic of both the primary cell lines. Foci of lymphocytic infiltrates, tumoural necrosis, often with pseudopallisading, and peritumoural edema were consistent features of all tumours. Limited parenchymal and more extensive perivascular tumoural invasion was seen predominantly in tumours containing the C6 cell line. There were no significant differences in GFAP, vimentin and HSP70 staining between the mixed tumours, although the pure F98 and A15A5 tumours were, unlike the pure C6 gliomas, S-100 negative. Using PCNA expression as a measure of the tumour proliferation all except the tumours derived from the three cell lines mix, which had a staining index of 7–10%, had focal staining indices in viable tumour of between 40–80%. There was focal positive staining in both perilesional brain and in regions of all tumours for the macrophage markers ED-1 and ED-2. None of the three cell lines stained in vitro for either ED1 and ED2 but all were constitutively positive in vitro for OX-6, a proposed marker for antigen presenting cells. The macrophage and lymphocytic response suggest a vigorous but largely ineffective immunological response had been mounted against all tumours. The consistent failure of the triple mix tumours to grow is unexplained. This work has shown the feasibility of producing ‘mixed’ cell line experimental gliomas by combining two cell lines at the time of innoculation. However, the relative failure to produce (i) mixed tumours that have properties not inherent to either parent cell line and (ii) implantation glioma with three cell lines suggest there are limits to this approach. Admixture of cell lines at the time of implantation therefore does not make experimental glioma models that more closely resemble natural gliomas, and also has some particular disadvantages. This experimental approach is therefore not recommended for use in the study of tumour biology and in evaluating the effectiveness of novel therapies.
引用
收藏
页码:231 / 242
页数:11
相关论文
共 50 条
  • [31] Programmed death ligand 1 gene silencing in murine glioma models reveals cell line-specific modulation of tumor growth in vivo
    Blomberg, Evelina
    Silginer, Manuela
    Roth, Patrick
    Weller, Michael
    NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)
  • [32] Borotrimethylglycylphenylalanine as a potential boron carrier for boron neutron capture therapy on malignant brain tumors: a study on human glioma cell line
    Takagaki, M
    Ono, K
    Masunaga, S
    Kinashi, Y
    Suzuki, M
    Powell, W
    Sood, A
    Spielvogel, BF
    ADVANCES IN NEUTRON CAPTURE THERAPY, VOLS I AND II: VOL I: MEDICINE AND PHYSICS, VOL II: CHEMISTRY AND BIOLOGY, 1997, 1132 : B491 - B496
  • [33] N-glycosylation of the EGF receptor expressed in a human glioma cell line, U373 MG, can modulate receptor function.
    Rebbaa, A
    Bremer, E
    Kim, P
    Meuillet, E
    Saito, T
    Taniguchi, N
    Moskal, JR
    Yamamoto, H
    GLYCOBIOLOGY, 1996, 6 (07) : 701 - 701
  • [34] A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell-Delivered TRAIL in Experimental Glioma Models
    Bagci-Onder, Tugba
    Wakimoto, Hiroaki
    Anderegg, Maarten
    Cameron, Cody
    Shah, Khalid
    CANCER RESEARCH, 2011, 71 (01) : 154 - 163
  • [35] Establishment of malignantly transformed dendritic cell line SU3-ihDCTC induced by Glioma stem cells and study on its sensitivity to resveratrol
    Xifeng Fei
    Anqi Wang
    Delin Wang
    Xan Meng
    Jiawei Ma
    Lei Hong
    Ruwei Qin
    Aidong Wang
    Jun Dong
    Qiang Huang
    Zhimin Wang
    BMC Immunology, 19
  • [36] Establishment of malignantly transformed dendritic cell line SU3-ihDCTC induced by Glioma stem cells and study on its sensitivity to resveratrol
    Fei, Xifeng
    Wang, Anqi
    Wang, Delin
    Meng, Xan
    Ma, Jiawei
    Hong, Lei
    Qin, Ruwei
    Wang, Aidong
    Dong, Jun
    Huang, Qiang
    Wang, Zhimin
    BMC IMMUNOLOGY, 2018, 19
  • [37] ABSENCE OF NEURON-ASSOCIATED MICROTUBULE PROTEINS IN THE RAT C-6 GLIOMA CELL-LINE - A COMPARATIVE IMMUNOBLOT AND IMMUNOHISTOCHEMICAL STUDY
    ZIENTEK, GM
    HERMAN, MM
    KATSETOS, CD
    FRANKFURTER, A
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1993, 19 (04) : 346 - 349
  • [38] P-31 NUCLEAR MAGNETIC-RESONANCE STUDY OF THE C6 GLIOMA CELL-LINE CULTURED ON MICROCARRIER BEADS
    VIONDURY, J
    GALONS, JP
    FANTINI, J
    CONFORTGOUNY, S
    KRIAT, M
    COZZONE, PJ
    BRAIN RESEARCH, 1989, 493 (01) : 175 - 178
  • [39] OCCURRENCE OF 2 DIFFERENT INTERMEDIATE FILAMENT PROTEINS IN THE SAME FILAMENT INSITU WITHIN A HUMAN GLIOMA CELL-LINE - AN IMMUNOELECTRON MICROSCOPICAL STUDY
    SHARP, G
    OSBORN, M
    WEBER, K
    EXPERIMENTAL CELL RESEARCH, 1982, 141 (02) : 385 - 395
  • [40] Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo
    Aulwurm, S
    Wischhusen, J
    Friese, M
    Borst, J
    Weller, M
    INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (07) : 1728 - 1735